Move it: Study finds exercise important part of diet plan

“New year, new me” is a saying of plenty of people utter when making New Year’s resolutions. Losing troublesome weight is a common goal. New research published in Applied Physiology, Nutrition, and Metabolism says that the most promising way of fulfilling your resolution is to follow a plan that requires exercise in addition to dieting.

Comparing weight loss plans that pressed the need for exercise and those that only recommended it, the study included 133 overweight women and paired them with some of the biggest names in weight loss. The Curves Complete 90-day Challenge, the only plan to include exercise and diet, was tested against Weight Watchers Points Plus, Jenny Craig At Home and Nutrisystem Advance Select.

"Jumping in with a better diet, aerobic and resistance training can be intimidating and overwhelming. Start with what you can manage, if that is all three—great; if not, pick the one you are most likely to stick with, get comfortable with that and then add another component," said Conrad Earnest, PhD. "You'll also benefit from the fact that adding exercise to a healthy diet or diet program improves health and sets the stage for weight maintenance later on."

Read the full study by clicking the link below:

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.